Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLonE-specific CAR T cells
- Development stage
- Unknown
- Lead developer
- Heidelberg University Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CLonE-specific CAR T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Heidelberg University Hospital (Universitätsklinikum Heidelberg) for the treatment of relapsed or refractory immunoglobulin light chain (AL) amyloidosis. These CAR T cells are engineered to express a receptor targeting the B-cell maturation antigen (BCMA), a protein highly expressed on the surface of the malignant plasma cell clone responsible for the production of amyloidogenic light chains. By specifically targeting and eliminating these plasma cells, the therapy aims to halt the production of toxic light chains and facilitate organ recovery. The "CLonE" designation is used specifically within the context of the clinical program for AL amyloidosis, distinguishing it from other BCMA-targeted therapies developed by the same institution.
- Other names
- BCMA-specific CAR T cellsCLonE CAR-T
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CLonE-specific CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLonE-specific CAR T cells.